| Literature DB >> 20173735 |
Jacques Fellay1, Alexander J Thompson, Dongliang Ge, Curtis E Gumbs, Thomas J Urban, Kevin V Shianna, Latasha D Little, Ping Qiu, Arthur H Bertelsen, Mark Watson, Amelia Warner, Andrew J Muir, Clifford Brass, Janice Albrecht, Mark Sulkowski, John G McHutchison, David B Goldstein.
Abstract
Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and is associated with a range of treatment-limiting adverse effects. One of the most important of these is RBV-induced haemolytic anaemia, which affects most patients and is severe enough to require dose modification in up to 15% of patients. Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20173735 DOI： 10.1038/nature08825
Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962